氯吡格雷防御冠心病介入治疗致心血管病变的效果及安全性观察

Effect and safety of clopidogrel in preventing cardiovascular disease induced by interventional therapy of coronary heart disease

目的研究分析冠心病介入治疗患者采用氯吡格雷防御心血管病变的效果及安全性。方法本次研究课题以94例冠心病介入治疗患者作为观察主体,均于2018年11月—2019年12月纳入。根据电脑随机分组方法,将之分成两个小组进行对照,其中常规组47例服用噻氯匹定;研究组47例服用氯吡格雷。结果研究组与常规组服药之后的血小板聚集率、血栓素B2均显著降低,且研究组下降幅度更优,与常规组差异显著(P<0.05);研究组术后凝血功能与常规组无差异(P>0.05);研究组术后不良反应更少,与常规组差异显著(P<0.05)。结论实施介入治疗的冠心病患者,服用氯吡格雷之后,凝血功能、血小板聚集、血栓素B2等观察指标显著改善,有效预防了心血管病变,同时还减少了术后不良反应,值得引起临床重视。

Objective To study the effect and safety of clopidogrel in the prevention of cardiovascular disease in patients with coronary heart disease undergoing interventional therapy. Methods Totally 94 cases of patients with coronary heart disease treated by interventional therapy were selected as the observation subjects in this study, which were included from November 2018 to December 2019. According to the computer random grouping method, they were divided into two groups for control, including 47 cases in the conventional group taking ticlopidine and 47 cases in the study group taking clopidogrel. Results The platelet aggregation rate and thromboxane B2 in the study group and the conventional group were significantly decreased, and the decrease range of the study group was better than that of the conventional group(P<0.05);There was no difference in the coagulation function between the study group and the conventional group(P>0.05);The adverse reactions in the study group were less than those in the conventional group(P<0.05). Conclusion After taking clopidogrel, the blood coagulation function, platelet aggregation, thromboxane B2 and other observation indexes in patients with coronary heart disease undergoing interventional therapy are significantly improved, which can effectively prevent cardiovascular disease and reduce postoperative adverse reactions, which is worthy of clinical attention.